title: The significance of Erb-b2 immunostaining in cervical cancer.
abstract: OBJECTIVE
  The aim of this study was to assess the relationship between survival and erb-b2 immunohistochemical staining in patients with early stage cervical carcinoma.
  
  
  METHODS
  Archival specimens for 126 patients with stage IB/IIA cervical carcinoma treated with radical hysterectomy and bilateral pelvic node dissection (RH-BPND) were retrieved and submitted to immunohistochemistry for ERBB2 expression. The association between positive results and poor survival was assessed in a multivariate analysis.
  
  
  RESULTS
  Erb-b2 immunostaining was significantly associated with poor survival (P = 0.0284) but less so than parametrial extension (P = 0.0014) and nodal disease (P = 0.0106). Tumor type (squamous/adenosquamous/adenocarcinoma) and the status of surgical margins were not significantly associated with survival.
  
  
  CONCLUSIONS
  These results supported further investigations of ERBB2 expression as a marker of high-risk disease in patients treated with RH-BPND.
authors.affiliation: Department of Gynaecological Oncology, University of Cape Town, Cape Town, South Africa.
authors.forename: J
authors.initials: J
authors.lastname: Nevin
authors.forename: D
authors.initials: D
authors.lastname: Laing
authors.forename: P
authors.initials: P
authors.lastname: Kaye
authors.forename: T
authors.initials: T
authors.lastname: McCulloch
authors.forename: R
authors.initials: R
authors.lastname: Barnard
authors.forename: P
authors.initials: P
authors.lastname: Silcocks
authors.forename: T
authors.initials: T
authors.lastname: Blackett
authors.forename: M
authors.initials: M
authors.lastname: Paterson
authors.forename: F
authors.initials: F
authors.lastname: Sharp
authors.forename: P
authors.initials: P
authors.lastname: Cruse
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000401:mortality*; D018196:Carcinoma, Adenosquamous / Q000737:chemistry* / Q000401:mortality*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000401:mortality*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015999:Multivariate Analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000401:mortality*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases